REGNThe muscle-loss problem just got a potential fix
Regeneron popped up at the EASD Annual Meeting with a not-so-small claim: in its Phase 2 COURAGE trial, trevogrumab helped prevent lean mass and muscle loss while people were losing weight on a GLP-1 receptor agonist like semaglutide. That matters because the GLP-1 party has a catch — yes, the scale moves, but some of that weight loss can come from muscle too.
In a predefined MRI substudy, trevogrumab prevented 70% of the muscle loss tied to semaglutide treatment. That’s the kind of stat that makes obesity investors lean forward a little, because a drug that helps people slim down without cannibalizing muscle could be a nicer pitch to doctors, patients, and payers alike.
Why the subgroup matters
Regeneron also said a pre-specified subgroup analysis found patients who met the low lean mass definition for sarcopenia lost more lean mass on semaglutide, and preserved more of it with trevogrumab. In plain English: the people most at risk of getting steamrolled by muscle loss may be the ones who benefit most from the add-on.
The bigger play
The data were presented at EASD and are in press with The Lancet, which gives the story a little extra scientific shine. Big picture: if GLP-1 drugs are the main character in obesity, trevogrumab is trying to become the loyal sidekick that keeps the hero from skipping leg day.